Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Items 201–300 of 684
Guo, C., Hu, M., DeOrazio, R. J., Usyatinsky, A. Y., Fitzpatrick, K., Zhang, Z., Maeng, J.-H., Kitchen, D. B., Tom, S., Luche, M., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.04.036 · Cited by 43
Sadurní, A., Kehr, G., Ahlqvist, M. M., Wernevik, J., Sjögren, H. P., Kankkonen, C., Knerr, L., & Gilmour, R. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201705373 · Cited by 46
Hussain, N., & Hussain, A. (2021) · RSC Advances · doi:10.1039/d1ra06351k · Cited by 44
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Lamos, E. M., Younk, L. M., & Davis, S. N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.909407 · Cited by 43
“Dapagliflozin, administered as a single oral dose in streptozotocin (STZ)-treated rats, induced a 55% reduction in blood glucose [26].”
BackgroundKaskadenreaktionen in der Totalsynthese von Akuammilin‐Alkaloiden
Smith, J. M., Moreno, J., Boal, B. W., & Garg, N. K. (2014) · Angewandte Chemie · doi:10.1002/ange.201406866 · Cited by 42
Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment
Brahmachari, G. (2011) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814335386_0001 · Cited by 65
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
Bacha, F. F., & Bartz, S. K. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12337 · Cited by 45
Shao, H., Zhai, S., Zou, D., Mir, M. U., Zawadzki, N. K., Shi, Q., Liu, S., & Shi, L. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1257978 · Cited by 44
Ferrannini, E. (2011) · Diabetes · doi:10.2337/db10-1667 · Cited by 41
Ma, F., Liu, J., Zhou, T., Lei, M., Chen, J., Wang, X., Zhang, Y., Shen, X., & Hu, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.028 · Cited by 41
Heo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 43
“Pharmaceutical companies have focused on the synthesis of phlorizin structure-based analogs that overcome these shortcomings with selectivity against SGLT2, resulting in the development of a phlorizin C-glucoside derivative dapagliflozin in 2008 [133].”
BackgroundA convenient synthesis of novel pyranosyl homo-C-nucleosides and their antidiabetic activities
Bisht, S. S., Jaiswal, N., Sharma, A., Fatima, S., Sharma, R., Rahuja, N., Srivastava, A. K., Bajpai, V., Kumar, B. N., & Tripathi, R. P. (2011) · Carbohydrate Research · doi:10.1016/j.carres.2011.03.006 · Cited by 40
Dapagliflozin: more than just another oral glucose-lowering agent?
Katsiki, N., Παπάνας, Ν., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.539558 · Cited by 39
“The effects of dapagliflozin treatment on lowering plasma glucose levels have been investigated in both animals [15,16] and humans [17-21].”
BackgroundFinding New Molecular Targets of Familiar Natural Products Using In Silico Target Prediction
Mayr, F., Möller, G., Garscha, U., Fischer, J., Castaño, P. R., Inderbinen, S. G., Temml, V., Waltenberger, B., Schwaiger, S., Hartmann, R. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197102 · Cited by 46
Stereoselectivity in the Lewis Acid Mediated Reduction of Ketofuranoses
van Rijssel, E. R., van Delft, P., van Marle, D. V., Bijvoets, S., Lodder, G., Overkleeft, H. S., van der Marel, G. A., Filippov, D. V., & Codée, J. D. C. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00419 · Cited by 37
SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes
Kinne, R. K.-H., & Castañeda, F. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_5 · Cited by 37
“Moreover, the high specificity of some SGLT inhibitors, such as sergliflozin (Katsuno et al. 2007), dapagliflozin ( Meng et al. 2008 ) and canagliflozin (Nomura et al. 2010), precludes any negative gastrointestinal side effects associated with SGLT1 inhibition.”
BackgroundMaurer, T. S., Ghosh, A., Haddish‐Berhane, N., Sawant‐Basak, A., Boustany, C., She, L., Leininger, M. T., Zhu, T., Tugnait, M., Yang, X., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9297-2 · Cited by 38
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Tahrani, A. A., & Barnett, A. H. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0007-3 · Cited by 40
Lv, B., Xu, B., Feng, Y., Peng, K., Xu, G. Z., Du, J., Zhang, L., Zhang, W., Zhang, T., Zhu, L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.088 · Cited by 37
Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
Carlson, G. F., Tou, C., Parikh, S. J., Birmingham, B. K., & Butler, K. A. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0003-2 · Cited by 38
Li, Y., Shi, Z., Chen, L., Zheng, S., Li, S., Xu, B., Liu, Z., Liu, J., Deng, C., & Ye, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01818 · Cited by 41
SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review
Manoj, A., Das, S., Ramachandran, A. K., Alex, A. T., & Joseph, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0154 · Cited by 39
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Cuypers, J., Mathieu, C., & Benhalima, K. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3349 · Cited by 44
“Dapagliflozin Preclinical trials have shown that dapagliflozin is a highly selective SLGT2-inhibitor, leading to a dose-dependent glycosuria and significant reduction in blood glucose levels compared to controls (13).”
BackgroundTanday, N., Irwin, N., Flatt, P. R., & Moffett, R. C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114009 · Cited by 36
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice
Katsuno, K., Fujimori, Y., Ishikawa-Takemura, Y., & Isaji, M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.07.001 · Cited by 40
Ji, Q., Xu, X., Ma, E., Liu, J., Basdeo, S., Liu, G., Mylott, W. R., Jr., Boulton, D. W., Shen, J. X., Stouffer, B. C., et al. (2015) · Analytical Chemistry · doi:10.1021/ac5037523 · Cited by 34
Tirucherai, G., LaCreta, F. P., Ismat, F. A., Tang, W., & Boulton, D. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12638 · Cited by 36
“Dapagliflozin is a potent, highly selective and orally active inhibitor of the human renal sodium glucose co-transporter type 2 (SGLT2), the major transporter responsible for renal glucose reabsorption [9].”
BackgroundSodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
da Silva, P. N., da Conceição, R. A., Maia, R. D. C., & Barbosa, M. L. D. C. (2018) · MedChemComm · doi:10.1039/c8md00183a · Cited by 37
Mascitti, V., Thuma, B. A., Smith, A. C. T., Robinson, R. P., Brandt, T. A., Kalgutkar, A. S. S., Maurer, T. S., Samas, B., & Sharma, R. (2012) · MedChemComm · doi:10.1039/c2md20163a · Cited by 34
Walczak, M. A. A., Zhu, F., & Yang, T. (2017) · Synlett · doi:10.1055/s-0036-1589020 · Cited by 34
Cai, W., Wu, J., Liu, W., Xie, Y., Liu, Y., Zhang, S., Xu, W., Tang, L., Wang, J., & Zhao, G. (2018) · Molecules · doi:10.3390/molecules23020252 · Cited by 34
“Initial attempts to directly reduce benzylic alcohol 22 to 24 with Et3SiH/BF3·Et2O [44], NaBH4/AlCl3 [45] or 57%HI/AcOH [46] were unsuccessful because no reaction occurred for the first reagent, a side reaction of AlCl3-mediated dechlorination predominated for the second one and the reaction proceeded considerably slo…”
BackgroundInfluentialSodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
Afşar, B., Afşar, R. E., Demiray, A., Altay, S., Korkmaz, H., Yıldız, A., Covic, A. C., Ortíz, A., & Kanbay, M. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac029 · Cited by 35
“dence of hyperfiltration and albuminuria [64, 65], so the findings in PCK rats were surprising [63].”
The Emerging Utility of Co-Crystals in Drug Discovery and Development
Meanwell, N. A. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00022-5 · Cited by 33
Synthesis of the Carbon Framework of Scholarisine A by Intramolecular Oxidative Coupling
Watanabe, T., Umezawa, N., Kato, N., & Higuchi, T. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201203454 · Cited by 32
Organo-zinc Promoted Diastereoselective C-Arylation of 1,2-Anhydrosugars from Arylboronic Acids
Tatina, M. B., Kusunuru, A. K., & Mukherjee, D. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b02364 · Cited by 33
Chung, I., Rajakumar, G., Subramanian, U., Venkidasamy, B., Khanna, V. G., & Thiruvengadam, M. (2019) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1853 · Cited by 34
Kim, J., Kim, D. K., Choi, W.-G., Ji, H., Choi, J., Song, I., Lee, S., & Lee, H. S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090865 · Cited by 32
“UGT1A9 was involved in the formation of dapagliflozin-3-O-glucuronide, a major in vivo metabolite of dapagliflozin [23,28].”
BackgroundInfluentialUse of SGLT2 inhibitors during Ramadan: An expert panel statement
Hassanein, M. M., Bashier, A. M., Randeree, H. A., ABOUELMAGD, M. M., Albaker, W. I., Afandi, B. O., Abu-Hijleh, O., Shaltout, I., EI-Sharkawy, M., Dağdelen, S., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108465 · Cited by 35
Xu, B., Feng, Y., Cheng, H., Song, Y., Lv, B., Wu, Y., Wang, C., Li, S., Xu, M., Du, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.032 · Cited by 32
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
Pfister, M., Whaley, J. M., Zhang, L., & List, J. F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.16 · Cited by 32
Self-citationDapagliflozin for the Treatment of Type 2 Diabetes
Brooks, A. M., & Thacker, S. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m212 · Cited by 32
Photoredox/Copper Dual-Catalyzed Benzylic C–H Esterification via Radical-Polar Crossover
Zhang, Y., Jiang, Y., Wang, Y., Sun, T., Meng, Y.-J., Huang, Y., Lv, X., Gao, J., Zhang, X., Zhang, S., et al. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c00763 · Cited by 31
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
“Dapagliflozin [103] was the first high-potency SLGT2-i to be created, followed by canagliflozin [104], empagliflozin [105], and ertugliflozin [106].”
BackgroundGutmann, A., & Nidetzky, B. (2013) · Pure and Applied Chemistry · doi:10.1351/pac-con-12-11-24 · Cited by 32
A Concise and Efficient Synthesis of Dapagliflozin
Yu, J., Cao, Y., Yu, H., & Wang, J. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00141 · Cited by 30
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
Chen, L., Ma, S., Hu, D., Lin, H., Zhu, Y., Chen, K., Chen, L., Zheng, C., Liu, J., & Liao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561494 · Cited by 29
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
Wu, J., Peng, Y., Wu, J., Hsieh, C., Wu, S., Coumar, M. S., Song, J., Lee, J., Tsai, C., Chen, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101080v · Cited by 29
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors
Koga, Y., Sakamaki, S., Hongu, M., Kawanishi, E., Sakamoto, T., Yamamoto, Y., Kimata, H., Nakayama, K., Kuriyama, C., Matsushita, Y., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.048 · Cited by 29
Chen, Z., Wang, R., & Qing, F. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.02.062 · Cited by 29
Zhao, M. M., Zhang, H., Iimura, S., Bednarz, M. S., Song, Q., Lim, N., Yan, J. R., Wu, W., Dai, K., Gu, X., et al. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00359 · Cited by 28
Dapagliflozin for the treatment of type 2 diabetes
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.812632 · Cited by 33
Henschke, J. P., Wu, P., Lin, C., Chen, S., Chiang, P., & HSIAO, C. ‐. (2015) · The Journal of Organic Chemistry · doi:10.1021/jo502839e · Cited by 30
Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
Lee, J., Kim, J. Y., Choi, J.-S., Lee, S.-H., Kim, J., & Lee, J. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.103 · Cited by 28
Theofilis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13020497 · Cited by 34
“Dapagliflozin was the first high-potency SLGT2i to be discovered [86], followed by canagliflozin [87], empagliflozin [88], and ertugliflozin [89].”
BackgroundCoMFA and CoMSIA studies onC-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
Vyas, V. K., Bhatt, H., Patel, P. K., Jalu, J., Chintha, C., Gupta, N., & Ghate, M. D. (2013) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2012.751553 · Cited by 27
Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
Lee, S., Song, K., Kim, J. Y., Kang, M., Lee, J. S., Cho, S.-H., Park, H., Kim, J., & Lee, J. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.014 · Cited by 27
Gerich, J. E., & Bastien, A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.54 · Cited by 28
Development of a Scalable Synthesis of Tofogliflozin
Ohtake, Y., Emura, T., Nishimoto, M., Takano, K., Yamamoto, K., Tsuchiya, S., Yeu, S.-Y., Kito, Y., Kimura, N., TAKEDA, S., et al. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b02734 · Cited by 27
C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents
Ding, Y., Mao, L., Xu, D., Xie, H., Yang, L., Xu, H., Geng, W., Gao, Y., Xia, C., Zhang, X., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.040 · Cited by 27
Nakachi, S., Okamoto, S., Tamaki, K., Nomura, I., Tomihama, M., Nishi, Y., Fukushima, T., Tanaka, Y., Morishima, S., Imamura, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112864 · Cited by 26
Azizogli, A., Vitti, M., Mishra, R., Osorno, L., Heffernan, C., & Kumar, V. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300143 · Cited by 36
Dapagliflozin: a review on efficacy, clinical effectiveness and safety
Paisley, A. N., Yadav, R., Younis, N., Rao‐Balakrishna, P., & Soran, H. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740009 · Cited by 27
“It is also over 1,000 times more selective for SGLT2 than SGLT1 (Figure 1) [13].”
BackgroundTurning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
Patel, A. K., & Fonseca, V. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0095-5 · Cited by 28
“After a single dose of dapagliflozin to streptozotocin-induced diabetic rats, there was an approximate 55% reduction in glucose compared with control in a 5-hour interval [21].”
BackgroundMethodNovel therapeutic agents for the treatment of diabetic kidney disease
Hartman, R. E., Rao, S., Churchwell, M. D., & Lewis, S. J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1811231 · Cited by 27
Lei, L., Liu, Q., Liu, S., Huan, Y., Sun, S., Chen, Z., Li, L., Feng, Z., Li, Y., & Shen, Z. (2015) · Metabolism · doi:10.1016/j.metabol.2015.06.014 · Cited by 26
O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
Xu, B., Lv, B., Feng, Y., Xu, G. Z., Du, J., Welihinda, A. A., Sheng, Z., Seed, B., & Chen, Y. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.030 · Cited by 26
N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors
Yamamoto, Y., Kawanishi, E., Koga, Y., Sakamaki, S., Sakamoto, T., Ueta, K., Matsushita, Y., Kuriyama, C., Tsuda-Tsukimoto, M., & Nomura, S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.042 · Cited by 25
The role of kidney in glucose homeostasis – SGLT2 inhibitors, a new approach in diabetes treatment
Andrianesis, V., & Doupis, J. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827399 · Cited by 25
Cine Substitution with Arylzinc Reagents: Scope and Mechanistic Studies
Barroso, S., Lemaire, S., Farina, V., Steib, A. K., Blanc, R., & Knochel, P. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b00074 · Cited by 25
Pan, X., Huan, Y., Shen, Z., & Liu, Z. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.053 · Cited by 25
Wang, Y., Lou, Y., Wang, J., Li, D., Chen, H., Zheng, T.-N., Xia, C., Song, X., Dong, T., Li, J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.032 · Cited by 27
Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Salvatore, T., Carbonara, O., Cozzolino, D., Torella, R., Nasti, R., Lascar, N., & Sasso, F. C. (2011) · Current Drug Metabolism · doi:10.2174/138920011796504509 · Cited by 30
Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
Kim, M. J., Lee, S., Park, S. O., Kang, H., Lee, J. S., Lee, K. N., Jung, M. E., Kim, J., & Lee, J. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.045 · Cited by 24
Novel avenues for treating diabetic nephropathy: new investigational drugs
Lacava, V., Pellicanò, V., Ferrajolo, C., Cernaro, V., Visconti, L., Conti, G., Buemi, M., & Santoro, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1293039 · Cited by 24
“SGLT2 inhibitors, including dapagliflozin, remogliflozin, and empagliflozin, are now widely approved as antihyperglycemic therapies [134].”
BackgroundMellander, A., Billger, M. A., JOHNSSON, E. K., Träff, A. K., Yoshida, S., & Johnsson, K. M. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0438-3 · Cited by 25
Xu, B., Feng, Y., Lv, B., Xu, G. Z., Zhang, L., Du, J., Peng, K., Xu, M., Dong, J., Zhang, W., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.04.088 · Cited by 23
Ohtake, Y., Sato, T., Matsuoka, H., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Higuchi, T., Murakata, M., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.005 · Cited by 23
An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
Adeghate, E. A., Mohsin, S., Adi, F., Ahmed, F., Yahya, A., Kalász, H., Tekes, K., & Adeghate, E. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1655539 · Cited by 23
“inhibitor in 2000 [17] and eventually the first specific SGLT2 inhibitor in 2008 [18].”
BackgroundKhalaf, R. A. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160414123602 · Cited by 24
Sipos, Á., Szennyes, E., Hajnal, N. É., Kun, S., Szabó, K. E., Uray, K., Somsák, L., Docsa, T., & Bokor, É. (2021) · Pharmaceuticals · doi:10.3390/ph14040364 · Cited by 25
Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans
Suzuki, M., Hiramatsu, M., Fukazawa, M., Matsumoto, M., Honda, K., Suzuki, Y., & Kawabe, Y. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12259 · Cited by 22
“Dapagliflozin [19], canagliflozin [20] and tofogliflozin [21] were synthesized in our laboratories at Chugai Pharmaceutical Co.”
BackgroundMethodMillar, P., Pathak, V., Moffett, R. C., Pathak, N., Bjourson, A. J., O’Kane, M., Flatt, P. R., & Gault, V. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.019 · Cited by 24
“SGLT2 is a high-capacity, low-affinity sodium glucose co-transporter which under normoglycemic conditions reabsorbs approximately 90% of glucose in the S1 segment of the promixal tubules (Hediger and Rhoads, 1994; Meng et al., 2008; Wright, 2001).”
Wagschal, S., Guilbaud, J., Rabet, P. T. G., Farina, V., & Lemaire, S. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01472 · Cited by 22
Chang, M., Liu, X., Cui, D., Liang, D., LaCreta, F. P., Griffen, S. C., Lubin, S., Quamina‐Edghill, D., & Boulton, D. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.004 · Cited by 21
SGLT Inhibitors: a Novel Target for Diabetes
Kanwal, A., & Banerjee, S. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.78 · Cited by 22
PARKINSON, J. R., Tang, W., Johansson, C., Boulton, D. W., & Hamrén, B. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12647 · Cited by 21
“Dapagliflozin is a potent, highly selective and orally active inhibitor of the human renal sodium-glucose co-transporter type 2, the major transporter responsible for renal glucose reabsorption [12].”
BackgroundChu, K.-F., Yao, C., Song, J., Chen, C., Yeh, T., Hsieh, T.-C., Huang, C.-Y., Wang, M., Wu, S., Chang, W.-E., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.058 · Cited by 21
MOP and EE Protecting Groups in Synthesis of α- or β-Naphthyl- C -Glycosides from Glycals
Choutka, J., Pohl, R., & Parkan, K. (2018) · ACS Omega · doi:10.1021/acsomega.8b00901 · Cited by 21
Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors
Mascitti, V., Robinson, R. P., Préville, C., Thuma, B. A., Carr, C. L., Reese, M. R., Maguire, R. J., Leininger, M. T., Lowe, A., & Steppan, C. M. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.02.024 · Cited by 21
Novel therapeutics and targets for the treatment of diabetes
Aicher, T. D., Boyd, S. A., McVean, M., & Celeste, A. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.1 · Cited by 22
Thiadiazole‐based Thioglycosides as Sodium‐glucose Co‐transporter 2 (SGLT2) Inhibitors
Gao, Y., Zhao, G., Liu, W., Wang, Y., Xu, W., & Wang, J. (2010) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201090120 · Cited by 21
Liu, J., Rajeshwaran, P., Hinrichs, F., Surke, M., Warratz, S., & Ackermann, L. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10732 · Cited by 20
“Pruning of biomolecules and natural products (PBNP)”: an innovative paradigm in drug discovery
Bathula, S. R., Murthy, A. S., Mainkar, P. S., & Chandrasekhar, S. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00403a · Cited by 20
Wang, L.-N., Niu, Y., Cai, Q.-H., Li, Q., & Ye, X. (2021) · Tetrahedron · doi:10.1016/j.tet.2021.131955 · Cited by 21
A Story of Serendipities: From Phlorizin to Gliflozins
Helvacı, Ö., & Helvacı, B. (2023) · Experimental and Clinical Transplantation · doi:10.6002/ect.iahncongress.25 · Cited by 23
Rao, M. L. N., & Dhanorkar, R. J. (2014) · RSC Advances · doi:10.1039/c3ra46672h · Cited by 20
Fushimi, N., Fujikura, H., Shiohara, H., Teranishi, H., Shimizu, K., Yonekubo, S., Ohno, K., Miyagi, T., Itoh, F., Shibazaki, T., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.037 · Cited by 23
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.